As of 2023, the share of US scientific publications among the world's top 10% cited in biotechnology represented a certain benchmark that forecasting suggests will see a gradual decline through 2028. The projected figures from 2024 to 2028 indicate a year-on-year decrease, suggesting a competitive landscape with enhanced contributions from other global players. A compound annual growth rate (CAGR) analysis over the five-year span reflects this diminishing trend at a steady rate.
Future trends to watch for include increasing international collaboration, the potential rise of emerging biotech hubs, and shifts in research funding and focus areas that could impact the US's standing in global biotechnology citations.
